115 results
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
24 Jan 24
Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
8:01am
for achieving long-lasting non-opioid pain control after painful surgical procedures,” said Bill Forbes, Executive Vice President, Chief Development … scores, fewer patients experiencing severe pain, and lower opioid consumption. ZYNRELEF was initially approved by the FDA in May 2021 and received
8-K
EX-99.1
HRTX
Heron Therapeutics Inc
11 Jan 24
Entry into a Material Definitive Agreement
4:07pm
Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
SAN DIEGO, January 7, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX
8-K
EX-99.1
annvqz
29 Dec 22
Other Events
9:10am
8-K
EX-99.2
8dxkr4g0ep0sa1
19 Sep 22
Other Events
8:00am
8-K
EX-99.1
rt05x55yn 5on
14 Jun 22
Regulation FD Disclosure
8:40am
8-K
plq1j1a
14 Jun 22
Regulation FD Disclosure
8:40am
8-K
EX-99.1
rcilui5jzrcus 1xl5sk
25 Mar 22
Regulation FD Disclosure
8:40am
8-K
EX-99.1
wnogbcs21522sp2w1fe
17 Mar 22
Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain
8:45am
8-K
EX-99.1
21n6u0
9 Dec 21
Other Events
8:05am
8-K
EX-99.1
4i69jp96x7958ocq4e3
13 May 21
Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours
8:25am